A clinical briefing for providers on Striverdi Respimat availability in 2026, including prescribing implications, alternatives, and patient access tools.
As a provider managing COPD patients, you've likely fielded calls from patients who can't find Striverdi Respimat (Olodaterol) at their pharmacy. While Striverdi is not on the FDA's active drug shortage list, real-world access barriers — including formulary exclusions, limited pharmacy stocking, and the absence of a generic alternative — continue to create challenges for patients prescribed this once-daily LABA.
This briefing covers the current state of Striverdi availability, prescribing considerations, cost and access dynamics, and tools you can use to help your patients stay on therapy.
Striverdi Respimat (Olodaterol hydrochloride inhalation spray) was FDA-approved on July 31, 2014, for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is manufactured exclusively by Boehringer Ingelheim.
Key milestones:
The current availability landscape has several practical implications for prescribers:
Several major PBMs, including Express Scripts, have excluded Striverdi Respimat from their national preferred formularies in favor of other COPD maintenance options. If your patient's plan doesn't cover Striverdi, they may face:
Before prescribing, consider verifying the patient's formulary status or prescribing a preferred alternative when clinically appropriate.
As of 2026, there is no FDA-approved generic Olodaterol. This limits cost-mitigation strategies for uninsured or underinsured patients. Patent protections remain in place, and no ANDA filings for generic Olodaterol inhalation products have been publicly reported.
Striverdi Respimat carries the class-wide LABA boxed warning regarding increased risk of asthma-related death. Striverdi is not indicated for asthma and should only be prescribed for COPD. Ensure patients understand this distinction, particularly those with overlapping asthma-COPD diagnoses.
Striverdi Respimat is not on the FDA's drug shortage list as of March 2026. Boehringer Ingelheim continues to manufacture and distribute the product. However, real-world availability varies:
Understanding the financial landscape helps you guide patients effectively:
For a comprehensive patient-facing resource on pricing, direct patients to: How to save money on Striverdi in 2026.
Several resources can help you and your patients navigate Striverdi access:
Medfinder offers a pharmacy availability search that can help identify which pharmacies near your patient's location have Striverdi in stock. This can be especially useful for front-desk staff helping patients locate medications after a visit.
The manufacturer provides several access programs:
If your patient's plan requires prior authorization, most EHR systems support electronic PA submission. Consider pre-emptively documenting the clinical rationale for Striverdi when prescribing for patients on restrictive formularies.
When Striverdi is unavailable or not covered, consider these alternatives:
Selection should be guided by the patient's clinical profile, device preference, insurance coverage, and cost considerations. For a patient-facing guide to these options, see: Alternatives to Striverdi.
The COPD inhaler landscape continues to evolve. Key trends to watch in 2026 and beyond:
While Striverdi Respimat remains a clinically effective option for COPD maintenance therapy, access challenges in 2026 mean that prescribers need to be proactive. Verify formulary coverage before prescribing, familiarize your team with the manufacturer's savings programs, and use tools like Medfinder for Providers to help patients locate pharmacies with stock.
When Striverdi isn't accessible, thoughtful therapeutic substitution — guided by patient preference, device familiarity, and cost — can keep your patients on track.
For the companion patient-facing article, share: Striverdi shortage update: What patients need to know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
